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Abstract: Sex hormonal milieus during the female fertility cycle modulate the tumor vascular 
permeability of breast cancer. It has been proposed that the liposomal formulated doxorubicin 
(ie, Doxil), given at the menstrual/estrous stage with the predicted highest tumor vascular 
permeability, allows significantly increased drug retention in the breast tumor. In the current 
study, syngeneic murine 4T1 mammary tumors were established on the backs of female 
BALB/c mice and Doxil was administered at particular mouse estrous cycle stages. The results 
indicated that Doxil administration during certain times in the mouse estrous cycle was crucial 
for drug retention in 4T1 tumor tissues. Significantly higher drug concentrations were detected 
in the tumor tissues when Doxil was administered during the diestrus stage, as compared to 
when the drug injection was given at all other estrous stages. Our study also showed that the 
tumor-bearing mice exhibited nearly normal rhythmicity of the estrous cycle post drug injec-
tion, indicating the feasibility of continual injection of Doxil at the same estrous cycle stage. 
By using 4T1 cells cultured in vitro, we showed that progesterone (P4) significantly inhibited 
cell proliferation and the production of six tumor-derived cytokines, eg, sTNF-RI, CXCL-16, 
GM-CSF, MIP-1α, MIP-1γ, and Flt3-L. Some of these factors have been shown to be vascular 
modulators in diverse tissues. In this report, we demonstrated that the concentration of P4 in 
the plasma and/or estrous cycle stage of 4T1 tumor-bearing mice can be used to select the best 
time for administrating the liposomal anticancer drugs.
Keywords: progesterone, menstrual cycle, mouse mammary tumor, Doxil, breast cancer 
therapy
Introduction
Recent advances in cancer therapy have utilized nanovectors to deliver cytotoxic 
drugs in an attempt to reduce drug-related side effects, extend the serum half life, and 
improve cancer therapeutic efficiency. Breast cancer is a disease that usually features 
leaky blood vessels with high permeability. The defective vasculature architecture, 
created as a result of the rapid vascularization that is necessary to serve fast-growing 
cancers, coupled with poor lymphatic drainage, allows an enhanced permeation and 
retention (EPR) of nanoformulated drugs or nanodrugs.1,2 It is obvious that the vas-
cular permeability of tumor tissues directly correlates with the nanodrug retention 
in vivo. This feature can be utilized for enhancing cancer therapeutic efficacy. Because 
the vascular mediator plays an important role in modulation of tumor vascular per-
meability, administration of the vascular antagonists can significantly suppress the 
EPR effect in tumors.3 Rolipram, an anti-inflammatory drug, was incorporated into 
a nanoparticle and tested in a rat model of inflammatory bowel disease.4 The rats that International Journal of Nanomedicine 2010:5 222
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4T1 tumor cell implantation  
and Doxil injection
A single cell suspension of 4T1 tumor cells was prepared at 
2 × 105 cells/mL in basic DMEM cell culture medium. The 
cell suspension (50 µL/mouse) was inoculated by subcuta-
neous injection in the back of two groups of female cycling 
BALB/c mice. Tumor size (TS) was measured daily using a 
caliper (length × width × height). When tumors reached an 
average size of ∼1500 mm3, the mice were assigned to two 
experimental groups. One group of nine mice was treated 
with an intravenous injection of Doxil (pegylated liposomal 
doxorubicin; Ortho Biotech) at 9 mg/kg of body weight and 
euthanized 24 hours later. Tumor tissues were harvested and 
snap frozen in liquid nitrogen, and then stored at –80°C. 
A second group of 20 tumor-bearing mice was further divided 
into two groups of 10 mice each. One group received an 
intravenous injection of Doxil (as described above) and the 
second group (control) was injected with saline. Tumor size 
and estrous cycle stage were monitored daily for two weeks 
and the mice were euthanized at the end of this period. Tumor 
tissues were harvested, fixed in 10% buffered formalin, and 
embedded in paraffin.
Determination of doxorubicin (Dox) 
concentration in the 4T1 tumor tissues
Extracts of dissected frozen tumor tissues were prepared 
by extraction with chloroform/isopropanol (1:1)8,9 and used 
to determine doxorubicin concentration according to the 
method of Charrois.10 Briefly, tissues were homogenized, 
extracted with chloroform/isopropanol (1:1), and centri-
fuged at 15,000xg for 20 min. The upper aqueous layer 
was discarded and the lower organic layer containing the 
lipophilic Dox was used to determine Dox concentration. 
A second extraction of each tissue extract was prepared by 
adding 200 µL of the chloroform/isopropanol layer to a 
2-mL microcentrifuge tube containing 100 µL 10% Triton 
X-100, 200 µL water, and 1,500 µL acidified isopropanol 
(0.75 N HCl). The tubes were mixed thoroughly and Dox 
and its metabolites were extracted overnight at -20°C. The 
tubes were warmed to room temperature, vortexed for 5 min, 
and centrifuged at 15,000xg for 20 min. Dox in the lower 
layer was quantified fluorometrically (λexcitation 470 nm and 
λemission 590 nm). To correct for nonspecific background 
fluorescence, serum samples derived from drug-free mice 
were analyzed as controls. The data are represented as Dox 
micro equivalents/per mL tissue extraction (mean ± standard 
deviation [SD] of triplicate aliquots).
received the nanoformulated rolipram demonstrated a better 
response based on the myleoperoxide activities as compared 
to free rolipram.
The female fertility cycle of humans is characterized 
by rhythmic fluctuations of hypothalamic, hypophyseal, 
adrenal, and ovarian hormones. The dynamic balance among 
prolactin, follicle-stimulating hormone (FSH), luteinizing 
hormone (LH), cortisol, estrogen, and progesterone modu-
lates cellular proliferation in many organs, such as ovary, 
uterus, and breast. The rhythmic fluctuation of sex hormones 
during the menstrual cycle also controls breast cancer angio-
genesis and/or tumor vascular permeability. We previously 
proposed that this natural exiting mechanism could be used 
to increase the drug retention of nanoformulated anticancer 
drugs in breast cancer tissue.5 It was hypothesized that nano-
drugs (ie, Doxil; Centocor Ortho Biotech Inc., Horsham, 
PA, USA) given at the menstrual stage with the predicted 
highest cancer vascular permeability would allow signifi-
cantly increased drug retention in breast cancer tissue and, 
subsequently, result in the maximal cancer growth control. 
On the contrary, if nanodrugs are given at the menstrual stage 
with the predicted lowest cancer vascular permeability, drug 
retention within the cancer would be lower. In the current 
study, we show that Doxil administration can be optimized to 
achieve the highest drug retention in tumors by monitoring 
the host estrous cycle.
Materials and methods
Cell line and cell culture
The murine 4T1 mammary tumor cells obtained from the 
American Type Culture Collection (ATCC) were cultured and 
maintained at 37°C in a humidified incubator with 5% CO2. 
The cell culture medium consisted of Dulbecco’s modified 
Eagle’s medium (DMEM; Sigma, St. Louis, MO, USA), 10% 
fetal bovine serum (Gibco, Carlsbad, CA, USA), 2 mM L-
glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin 
(Gibco, Carlsbad, CA, USA).
Mice
Female virgin BALB/c mice (4–5 weeks old) were obtained 
from Charles River (Portage, MI) and housed with food 
and water provided ad libitum under a 12-hour lights on, 
12-hour lights off cycle. After two months (12–13 weeks 
of age), vaginal smears were performed daily using sterile 
saline washings and cell smears were stained with Diff Quick 
staining solution (JT Baker, NJ, USA). Stages of the mouse 
estrous cycle were identified by cytological evaluation of 
vaginal smears as described previously.6,7International Journal of Nanomedicine 2010:5 223
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Immunohistochemistry
Multiple sections (5-µm) were cut from each tumor tissue 
paraffin block and mounted on positively charged glass slides 
(Fisher Scientific, Pittsburgh, PA, USA). After deparaffiniza-
tion and hydration, the tissue slides were placed in a glass con-
tainer filled with citrate buffer (10 mM sodium citrate, 0.05% 
Tween 20, pH6.0) and heated in a microwave for 15 minutes for 
antigen retrieval. Endogenous peroxidase activity was blocked 
by incubating the slides in phosphate-buffered saline (PBS) 
containing 3% H2O2 for 15 minutes. Slides were then incubated 
in 5% normal horse serum for one hour at room temperature. 
Primary rabbit polyclonal antibody against nuclear progester-
one receptor (PR; diluted 1:400) or goat polyclonal antibody 
against membrane-associated progesterone receptor alpha 
(mPRα; diluted 1:200) (both from Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) was applied to slides followed by incu-
bation overnight at 4°C. Biotinylated anti-rabbit or anti-goat 
antibodies (dilutions 1:300; ImmPress Reagent Kit, Vector, 
Burlingame, CA, USA) were applied and the slides were incu-
bated for 30 minutes at room temperature. Between each step 
of the immunostains, slides were washed twice (5 min/each) 
in PBS buffer (pH 7.2). The color was developed by DAB 
substrate (Vector) and the sections were counterstained with 
hematoxylin. The immunostained slides were evaluated and 
photographed using a Nikon microscope (MICROPHOT-SA; 
Nikon, Tokyo, Japan) with a 40× objective and an Olympus 
digital camera (DP71; Olympus, Tokyo Japan).
Protein microarray assays for profiling  
the expression of tumor derived 
cytokines
The 4T1 tumor cells were cultured and treated with 
progesterone (P4; Sigma-Aldrich) at 0, 15 ng/mL, 30 ng/mL, 
and 60 ng/mL for 24 hours. Total cell lysates were 
prepared using500 µL of ice-cold cell lysis buffer, pH 
7.4 (50 mM HEPES, 5 mM EDTA, 50 mM NaCl, 1% 
Triton X-100, 10 µg/mL aprotinin, 1 mM phenylmeth-
ylsulfonyl fluoride, 10 µg/mL leupeptin, 50 mM sodium 
fluoride, 1 mM sodium orthovanadate, and 10 mM sodium 
pyrophosphate). The protein expression profiling analy-
ses were then conducted using a mouse cytokine antibody 
microarray (RayBiotech, Inc., Norcross, GA, USA). The 
analysis was done twice.
Cell proliferation assay
The XTT cell proliferation assay was performed according 
to the manufacturer’s protocol (Cayman Chemicals, Ann 
Arbor, MI, USA). Briefly, 4T1 cells were seeded in a 96-well 
plate (104–105 cells/100 µL/well) with P4 at 0, 15 ng/mL, 
30 ng/mL, and 60 ng/mL and incubated for 24 hours at 37°C. 
Reconstituted XTT mixture (10 µL) was added to each well 
and the cells were incubated for 2 hours at 37°C. Absorbance 
at 450 nm was measured using a microplate reader.
Progesterone treatment induced cell 
death in vitro
The 4T1 cells were seeded in 35 mm Petri dishes at concen-
tration of 2 × 105 cells/ml and cultured for 1–2 days. Growth 
medium was replaced with medium containing P4 (0, 15 ng/mL, 
30 ng/mL, or 60 ng/mL) when the cultures were 70% confluent 
and the cultures were incubated for an additional 24 hours. Cells 
were photographed using an inverted Olympus microscope with 
a 10 × objective and a digital camera.
Statistics
For all statistical analyses, a significance level of P  0.05 
was employed. A two-sided Student’s t-test was used to 
test the differences between the means of control and drug-
treated groups.
Results
The time of Doxil administration during 
mouse estrous cycle and its effects  
on drug retention in 4T1 tumors
To test our hypothesis, we conducted two animal experiments. 
For each experiment, subcutaneous murine 4T1 mammary 
tumors were established on the backs of female BALB/c 
mice. In the first group of mice, Doxil was injected when the 
4T1 tumors were ∼1,500 mm3 and the tumor-bearing mice 
were sacrificed 24 hours later. Tumor tissues were harvested 
and Dox concentration within each tumor was measured. As 
shown in Figure 1A, Dox concentrations in the 4T1 tumors 
were significantly higher (7.74 µ equivalents/mL, n = 3) when 
the drug was injected during the diestrus stage, as compared to 
those tumors when the drug was injected in all other estrous 
stages (1.38 µ equivalents/mL, n = 6; P = 0.01). These data 
suggest that the diestrus stage may represent the best time for 
Doxil injection in 4T1 tumor-bearing mice (Figure 1B).
Doxil administration and its effects on 
the growth of 4T1 tumors and estrous 
cycle rhythms of tumor‑bearing mice
In the second group of mice, estrous cycle and tumor sizes 
were monitored daily throughout the experiment, prior to International Journal of Nanomedicine 2010:5 224
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Figure 1 The time of Doxil administration during mouse estrous cycle and its effects on drug retention in 4T1 tumors. A) The Dox concentrations in 4T1 tumors when Doxil 
is injected during diestrus stage or other estrous stages. B) The dynamic changes of serum progesterone and estrogen levels during the estrous cycle. The concentrations of 
P4 and E2 in mice were previously published.13 The best time for Doxil injection is indicated by the black arrow and bar. The worst times for Doxil injection are indicated by 
small triangles and dotted bars.
and post-Doxil administration. As shown in Figures 2A 
and 2B, 4T1 tumor implantation and Doxil injection has 
little effect on the length of the estrous cycle and indi-
vidual estrous stages. The length of diestrus appears to be 
extended slightly from an average of 1.8 days to 2.5 days 
by Doxil injection. The difference, however, is not statisti-
cally significant (P  0.05). Figure 2C shows the sensitivity 
of implanted 4T1 tumors to Doxil treatment. Tumor size 
measurements were started in the second group of mice 
when implanted tumors were palpable (day 1). Tumors 
grew to the target size (1500 mm3) in about 13 days at 
which point mice were treated with either Doxil or saline. 
Average tumor size in the Doxil group decreased from 
1,504 mm3 to about 456 mm3 by day 28. In contrast, tumors 
in the control group continued to grow to over 2000 mm3 
by day 17. Tumor size was estimated for some mice due 
to tumor ulceration and the control mice were sacrificed 
due to poor physiological condition.
Expression of sex hormone  
receptors in 4T1 tumors
It is well known that 4T1 tumors are negative for ERα and 
nonresponsive to current endocrine therapeutics,11 which 
raises a question: How do 4T1 tumors respond to the rhyth-
mic fluctuations in sex hormones and regulate tumor growth 
and angiogenesis during the estrous cycle? In this study, 
we demonstrate the expression of nuclear PR and mPRα in 
4T1 tumors. As shown in Figure 3, strong positive staining 
for PR is seen in the nuclei of most 4T1 tumor cells (white 
arrows in Figure 3A), while only weak positive signals for 
mPRα are observed in the cytoplasm of tumor cells (yellow 
arrows in Figure 3B).
The effect of progesterone on the 
expression of tumor‑derived cytokines
Sex hormones are rhythmically changing during the mouse 
estrous cycle. Plasma levels of estradiol (E2) fluctuate International Journal of Nanomedicine 2010:5 225
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Figure 2 Doxil administration and its effects on the growth of 4T1 tumors and estrous cycle of tumor‑bearing mice. A) Length of estrous cycles that occur before and after Doxil 
injection. B) Length of estrous cycle stages in control and tumor‑bearing mice prior to and after Doxil administration. C) Effect of Doxil treatment on 4T1 tumor size.
between 3.1 and 10.5 pg/mL during mouse estrous cycle,12 
while plasma progesterone (P4) levels alternate between 
8 and 60 ng/mL. Diestrus in mice corresponds to the lowest 
plasma P4 concentration.13 To determine the potential effects 
of the dynamic P4 levels on tumor derived cytokine secre-
tion, the conditioned medium was harvested from 4T1 cell 
culture dishes and submitted to protein expression profiling 
analysis using a mouse cytokine antibody microarray. As 
shown in Figure 4, sTNF-RI, CXCL-16, GM-CSF, MIP-3α, 
MIP-1γ, and Flt3-L are decreased dramatically (P  0.05). 
Surprisingly, vascular endothelial growth receptor and 
basic fibroblast growth factor do not change as compared to 
vehicle-treated controls (data not shown).
The effects of P4 on cell proliferation  
and cell death
We also investigated the effects of P4 on cell proliferation 
and cell death of 4T1 tumor cells in vitro. As shown in 
  Figure 5A, a 30% reduction in cell proliferation is observed 
when 4T1 cells are treated with P4, as compared to vehicle-
treated controls. In contrast, there is about a 40% increase in 
cell proliferation when the cells are treated by E2 as a positive 
control. We further evaluated the growth status of 4T1 cells 
after P4 treatment. The number of dead cells or detached cells 
increases dramatically when cells are treated with increasing 
doses of P4 for 24 hours (Figure 5B).
Discussion
The enhanced vascular permeability and drug retention (EPR) 
theory, developed by Maeda and colleagues,1 is fundamental 
for nanoformulated drug or nanodrug delivery. The EPR 
effects of nanodrugs depend upon the enhanced tumor 
  angiogenesis, defective vascular architecture, impaired lym-
phatic drainage system, and increased production of vascular 
permeability mediators. It was proposed that the changes in 
breast cancer capillary permeability putatively respond to the 
sex hormone milieus during the menstrual cycle.7 According 
to our hypothesis, the best time for nanodrug administration 
is when the peak of serum drug concentration meets with 
the highest degree of tumor vascular permeability. On the 
contrary, the worst time for the administration is the converse; 
that is when the peak serum drug concentration meets with the 
lowest degree of tumor vascular permeability. We assumed 
that, if the dynamic changes of tumor vascular permeability 
during menstrual cycle are obvious, optimizing the time of 
nanodrug administration at proper menstrual cycle stage may International Journal of Nanomedicine 2010:5 226
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Figure 3 Immunohistochemical analysis of PR and mPRα protein expression in 4T1 tumor tissues. A) 4T1 tumor stained with H & E. B) Negative control of 4T1 tumor tissue 
stained without primary antibody. Magnification of all images is 400×. C) 4T1 tumor tissue stained with anti‑PR. D) 4T1 tumor tissue stained with anti‑mPRα.
Abbreviations: H & E, hematoxylin & eosin; PR, progesterone receptor; 4TI, mouse mammary cell line.
become crucial to increase the drug retention in breast cancer. 
In this study, we first observed higher drug retention in 4T1 
tumors when Doxil was injected during diestrus, indicat-
ing the best time for Doxil administration in this particular 
tumor/mouse model.
For the mouse model used, there are four estrous 
stages – diestrus (∼48–72 hours, the longest estrous stage), 
proestrus (12–14 hours), estrus (8–10 hours), and medes-
trus (24–36 hours). Enveloping doxorubicin in liposomal 
vesicles significantly extends the drug T1/2 from a few hours 
to about 55 hours.14 If Doxil is injected during one of the 
four estrous stages, the T1/2 of Doxil will cover two or three 
successive estrous cycle stages. For example, if Doxil is 
given at the diestrus stage, the T1/2 of the drug may cover 
diestrus, proestrus, and estrus. The serum concentration of P4 
  during this period starts at a low level and rises to the highest 
before dropping again (Figure 1B). It is assumed that the low 
serum concentration of P4 at the time of drug administration 
may have great impact on the production of tumor derived 
  cytokines and tumor vascular permeability and subsequently 
increase drug retention within tumors.
Conventional Dox is widely used for treatment of 
  metastatic breast cancer (MBC). The potential mechanistic 
actions of Dox include the inhibition of DNA topoisomerase 
and helicases causing cell S phase arrest.15–18 Although Dox 
is a widely used anticancer drug in the clinic, it has a number 
of undesirable side effects such as cardiotoxicity, myelosup-
pression, nephrositis, intestinal mucositis, and hair loss, 
which result in a very narrow therapeutic window. Another 
frequent side effect for premenopausal breast cancer patients International Journal of Nanomedicine 2010:5 227
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Figure 4 P4 treatment and cytokine expression in vitro. Scanned signal intensity of the hybridized protein array spots from a cytokine microarray assay of conditioned medium 
from 4T1 mouse mammary cell cultures treated with progesterone for 24 hours. Each bar represents the average values from two hybridized spots of duplicate assays with 
subtraction of the baseline reading (baseline reading value = 100).
treated with Dox is premature menopause or amenorrhea. 
Nearly all of the patients (96%) aged between 40–49 years 
develop amenorrhea.19 This is a concern for the proposed 
chronotherapeutic strategy. This side effect, however, can 
be prevented if the drug is formulated in nanovectors. 
Pegylated liposomal doxorubicin (Doxil) has been used in 
the treatment of human cancer patients for more than ten 
years.20 Among dozens of clinical studies with liposomal 
Dox, none of them, so far, has reported amenorrhea as a 
common side effect of this drug. In this study, we provide 
a piece of preclinical evidence suggesting that administra-
tion of Doxil does not disrupt the rhythmicity of the mouse 
estrous cycle during at least two successive weeks, indicating 
the feasibility of continual injection of Doxil at the same 
estrous cycle stage.
Previous studies have shown that the bacterial endotoxin 
(lipopolysaccharide [LPS])-induced growth and metastasis of 
murine 4T1 tumors in experimental mice are associated with 
increased angiogenesis and vascular permeability.21,22 The 
growth of 4T1 tumors in mice induces a leukemoid reaction 
with profound granulocytosis coincident with the production 
of tumor-derived growth factors. In addition, 4T1 tumor cells 
in culture express mRNA transcripts for chemokines, includ-
ing RANTES, MCP-1, and KC.23 These data demonstrate that 
4T1 tumor cells tend to produce a variety of inflammatory 
cytokines or chemokines to modulate the tumor cell growth 
and/or angiogenesis by paracrine or autocrine mechanisms. 
In this study, we demonstrated that progesterone inhibits 
the expression of numerous tumor-derived cytokines in vitro, 
such as sTNF-RI, CXCL-16, GM-CSF, MIP-1α, MIP-1γ, 
and Flt3-L. Some of these tumor derived cytokines, such as 
MIP-1α, CXCL16,24 sTNF-RI,25 are important mediators 
for the immune and inflammatory reactions within diverse 
tissues. Others, such as GM-CSF,26 are novel mediators for 
neovascularization and vascular permeability. Our data sup-
port the hypothesis that tumor growth and angiogenesis in 
mice are modulated by the dynamic sex hormone milieus 
throughout the estrous cycle.International Journal of Nanomedicine 2010:5 228
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Conclusions
The frequency of Doxil administration in the clinic is once 
every four weeks, which is approximately the same length 
as one human menstrual cycle. The proposed therapeutic 
strategy can therefore be easily adapted in human patients. 
In order to adapt this strategy to humans, the time of Doxil 
injection would need to be coordinated with the proper 
menstrual stage to correspond to the period of highest tumor 
vascular permeability. According to our hypothesis, the best 
time for Doxil administration may be when serum P4 is at 
the lowest concentration or the tumor cytokine production 
is at the highest point, both of which may correspond to 
the time of highest tumor vascular permeability. To further 
elucidate and confirm this proposed theory, experiments 
with larger groups of mice and diverse tumor cell models 
may be needed.
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